adenoviral vector encoding lacZ + dendritic cells

Adenoviral vector encoding lacZ + dendritic cells is an experimental cellular immunotherapy comprising autologous or allogeneic dendritic cells (DCs) that have been genetically modified (transduced) with a recombinant adenoviral vector carrying the *lacZ* gene. The *lacZ* gene encodes the enzyme beta-galactosidase, which in this context serves as a model tumor-associated antigen (TAA). The therapy leverages the potent antigen-presenting capabilities of dendritic cells to process and present beta-galactosidase-derived peptides via MHC molecules. This presentation is intended to prime and activate antigen-specific CD4+ and CD8+ T lymphocytes, as well as natural killer (NK) cells, to mount a robust immune response against cells expressing the target antigen. This construct is primarily utilized in preclinical oncology research to evaluate the mechanisms of gene-modified DC vaccines and to study the interplay between innate and adaptive immunity in anti-tumor responses.

Other names

Ad-lacZ-transduced dendritic cellslacZ-transduced dendritic cellsadenovirus-lacZ-transduced DCsbeta-galactosidase-expressing dendritic cells